Development of Optimized Exatecan-Based Immunoconjugates with Potent Antitumor Efficacy in HER2-Positive Breast Cancer

发表于 2026-7-31 14:10:14

期刊：Journal of Medicinal Chemistry

文献作者：Etienne Auvert; Emmanuel Douez; Louis Jolivet; Tiffany Witkowski; Anne-Catherine Jallas; Fanny Boursin; Ioana Molnar; Cyril Colas; Sandrine Valsesia Wittmann; Manon Auriol; Jean-Michel Chezal; Nicolas Aubrey; Emilie Allard-Vannier; Aurélie Maisonial-Besset; Nicolas Joubert; Caroline Denevault-Sabourin

出版日期：2025-9-25

DOI号：10.1021/acs.jmedchem.5c01184

下载链接：https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.5c01184

文献链接：https://doi.org/10.1021/acs.jmedchem.5c01184

当前文献来源于 American Chemical Society (ACS)。

备注信息：

发表于 2026-7-31 14:10:15

: 当前求助已完成，请重新发起求助。
已完结状态的附件将会在24小时内删除。

[ACS] Development of Optimized Exatecan-Based Immunoconjugates with Potent Antitumor Efficacy in HER2-Positive Breast Cancer

已采纳

同分类求助

最新回复

站点公告

今日热心研友

（热心研友QQ群）

[ACS] Development of Optimized Exatecan-Based Immunoconjugates with Potent Antitumor Efficacy in HER2-Positive Breast Cancer 一键复制